Bayer Announces Publication of Phase IV Adempas® (riociguat) Data in The Lancet Respiratory Medicine
Retrieved on:
Monday, March 29, 2021
Health, Clinical trials, Research, Science, Pharmaceutical, Cardiology, Biotechnology, Chemical compounds, Companies, Pyrimidines, Aspirin, Bayer, IG Farben, Leverkusen, Riociguat, Industry economics), Risk Evaluation and Mitigation Strategies, Rems, the REPLACE Study, Pulmonary Arterial Hypertension, Adempas® (riociguat), Bayer
For all female patients, Adempas is available only through a restricted program called the Adempas Risk Evaluation and Mitigation Strategy (REMS) Program.
Key Points:
- For all female patients, Adempas is available only through a restricted program called the Adempas Risk Evaluation and Mitigation Strategy (REMS) Program.
- Adempas, the first sGC stimulator of this collaboration, is developed by Bayer and MSD.
- For all female patients, Adempas is available only through a restricted program called the Adempas Risk Evaluation and Mitigation Strategy (REMS) Program.
- Our online press service is just a click away: www.bayer.us/en/newsroom
BAYER, the Bayer Cross, and Adempas(R) are registered trademarks of Bayer.